Lonza Group AG
LONN
Rangering i aksjer
#447
Lonza Group AG, together with its subsidiaries, operates as a contract... Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
Aksjekurs
$764.04
Markedsverdi
$53.36B
Endring (1 dag)
0.96%
Endring (1 år)
8.59%
Land
CH
Handel Lonza Group AG (LONN)
Kategori
Healthcare
P/B-forhold for Lonza Group AG (LONN)
P/B-forhold per 2026 TTM: 0
Ifølge Lonza Group AG sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/B-forhold på 0.
P/B-historikk for Lonza Group AG fra 2004 til 2026
P/B-forhold ved hvert års slutt
| År | P/B-forhold | Endre |
|---|---|---|
| 2025 | 4.12 | 0.78% |
| 2024 | 4.09 | 48.44% |
| 2023 | 2.76 | -13.17% |
| 2022 | 3.17 | -45.28% |
| 2021 | 5.80 | -6.60% |
| 2020 | 6.21 | 54.07% |
| 2019 | 4.03 | 31.99% |
| 2018 | 3.05 | 4.80% |
| 2017 | 2.91 | -20.51% |
| 2016 | 3.67 | -1.63% |
| 2015 | 3.73 | 46.34% |
| 2014 | 2.55 | 32.62% |
| 2013 | 1.92 | 76.08% |
| 2012 | 1.09 | -10.31% |
| 2011 | 1.22 | -26.13% |
| 2010 | 1.65 | 3.24% |
| 2009 | 1.59 | -44.54% |
| 2008 | 2.87 | -28.32% |
| 2007 | 4.01 | 12.01% |
| 2006 | 3.58 | 40.08% |
| 2005 | 2.56 | 8.33% |
| 2004 | 2.36 | 0.00% |
P/B-forhold for lignende selskaper eller konkurrenter
| Selskap | P/B-forhold | Forskjell i P/B-forhold | Land |
|---|---|---|---|
| 6.251 | - |
US
|
|
| 13.2547 | - |
US
|
|
| 4.4521 | - |
AU
|
|
| 6.3632 | - |
NL
|
|
| 3.2932 | - |
BE
|
